Company received favorable Medicare coverage expansion for its dd-cfDNA testing portfolio, which increases reimbursement clarity and testing frequency allowances. This supports the company's commercial strategy for in-house testing kits and expands its addressable market. The policy also cites iMDx-affiliated research, affirming scientific leadership. However, sentiment is tempered by the fact that GraftAssureDx still awaits FDA approval.
Also mentions IMDX
Articles that tag IMDX but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
